STTK · Shattuck Labs, Inc.

Shattuck Labs Inc Is A Biotechnology Company Specializing In The Development Of Potential Treatments For Inflammatory And Immune-Mediated Diseases. It Is Developing A Potentially First-In-Class Antibody For The Treatment Of Inflammatory Bowel Disease (Ibd) And Other Inflammatory And Immune-Mediated Diseases. The Company'S Expertise In Protein Engineering And The Development Of Novel Tumor Necrosis Factor (Tnf) Receptor Therapeutics Comes Together In Its Main Program, Sl-325, Which Has The Potential To Be A First-In-Class Death Receptor 3 (Dr3) Antagonist Antibody. In Addition, The Company Is Developing Sl-425, A Half-Life Extended Version Of Sl-325, And Multiple Other Preclinical Dr3-Based Bispecific Antibodies, For The Treatment Of Patients With Ibd.